Access to innovative therapies
The aims of our research are to discover cures for myeloid malignancies and to uncover methods for preventing the development of acute myeloid leukemia. Our unique program has allowed us to rapidly achieve breakthroughs in both basic research science and clinical trials in which patients can benefit from the latest innovations.
Malignant Hematology Clinical Trials
- High intensity (intermediate or high dose cytarabine [HiDAC]; mitoxantrone, etoposide, and cytarabine [MEC]; or fludarabine, cytarabine, granulocyte colony stimulating factor [G-CSF], +/- idarubicin [FLAG/FLAG-Ida]).
- Low intensity (low dose cytarabine [LDAC], decitabine, or azacitidine).